Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
161,353
archived clinical trials in
Cancer

Everolimus in Patients With Pancreatic Neuroendocrine Tumors Metastatic to the Liver Previously Treated With Surgery
A Randomized, Double-Blinded, Placebo-Controlled Phase II Study of Adjuvant Everolimus Following the Resection of Metastatic Pancreatic Neuroendocrine Tumors to the Liver
Status: Enrolling
Updated:  2/7/2017
Eastern Cooperative Oncology Group
mi
from
Boston, MA
Everolimus in Patients With Pancreatic Neuroendocrine Tumors Metastatic to the Liver Previously Treated With Surgery
A Randomized, Double-Blinded, Placebo-Controlled Phase II Study of Adjuvant Everolimus Following the Resection of Metastatic Pancreatic Neuroendocrine Tumors to the Liver
Status: Enrolling
Updated: 2/7/2017
Eastern Cooperative Oncology Group
mi
from
Boston, MA
Click here to add this to my saved trials
PD0332991 (Palbociclib) in Patients With Advanced or Metastatic Liposarcoma
A Phase II Study Of PD0332991 (Palbociclib) in Patients With Advanced or Metastatic Liposarcoma
Status: Enrolling
Updated:  2/8/2017
Memorial Sloan Kettering Cancer Center
mi
from
New York, NY
PD0332991 (Palbociclib) in Patients With Advanced or Metastatic Liposarcoma
A Phase II Study Of PD0332991 (Palbociclib) in Patients With Advanced or Metastatic Liposarcoma
Status: Enrolling
Updated: 2/8/2017
Memorial Sloan Kettering Cancer Center
mi
from
New York, NY
Click here to add this to my saved trials
AMG 319 Lymphoid Malignancy FIH
A Phase 1, First-in-Human Study Evaluating the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of AMG 319 in Adult Subjects With Relapsed or Refractory Lymphoid Malignancies
Status: Enrolling
Updated:  2/8/2017
Clinical Research Facility
mi
from
Salt Lake City, UT
AMG 319 Lymphoid Malignancy FIH
A Phase 1, First-in-Human Study Evaluating the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of AMG 319 in Adult Subjects With Relapsed or Refractory Lymphoid Malignancies
Status: Enrolling
Updated: 2/8/2017
Clinical Research Facility
mi
from
Salt Lake City, UT
Click here to add this to my saved trials
AMG 319 Lymphoid Malignancy FIH
A Phase 1, First-in-Human Study Evaluating the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of AMG 319 in Adult Subjects With Relapsed or Refractory Lymphoid Malignancies
Status: Enrolling
Updated:  2/8/2017
Clinical Research Facility
mi
from
Hackensack, NJ
AMG 319 Lymphoid Malignancy FIH
A Phase 1, First-in-Human Study Evaluating the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of AMG 319 in Adult Subjects With Relapsed or Refractory Lymphoid Malignancies
Status: Enrolling
Updated: 2/8/2017
Clinical Research Facility
mi
from
Hackensack, NJ
Click here to add this to my saved trials
AMG 319 Lymphoid Malignancy FIH
A Phase 1, First-in-Human Study Evaluating the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of AMG 319 in Adult Subjects With Relapsed or Refractory Lymphoid Malignancies
Status: Enrolling
Updated:  2/8/2017
Clinical Research Facility
mi
from
Durham, NC
AMG 319 Lymphoid Malignancy FIH
A Phase 1, First-in-Human Study Evaluating the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of AMG 319 in Adult Subjects With Relapsed or Refractory Lymphoid Malignancies
Status: Enrolling
Updated: 2/8/2017
Clinical Research Facility
mi
from
Durham, NC
Click here to add this to my saved trials
AZD9150, a STAT3 Antisense Oligonucleotide, in People With Malignant Ascites
A Pilot Study of AZD9150, a STAT3 Antisense Oligonucleotide in Malignant Ascites
Status: Enrolling
Updated:  2/8/2017
National Institutes of Health Clinical Center, 9000 Rockville Pike
mi
from
Bethesda, MD
AZD9150, a STAT3 Antisense Oligonucleotide, in People With Malignant Ascites
A Pilot Study of AZD9150, a STAT3 Antisense Oligonucleotide in Malignant Ascites
Status: Enrolling
Updated: 2/8/2017
National Institutes of Health Clinical Center, 9000 Rockville Pike
mi
from
Bethesda, MD
Click here to add this to my saved trials
Photon/Proton Radiation Therapy for Carcinoma of the Nasopharynx
A Clinical Outcomes Protocol of Photon/Proton Beam Radiation Therapy for Carcinoma of the Nasopharynx
Status: Enrolling
Updated:  2/9/2017
University of Florida Proton Therapy Institute
mi
from
Jacksonville, FL
Photon/Proton Radiation Therapy for Carcinoma of the Nasopharynx
A Clinical Outcomes Protocol of Photon/Proton Beam Radiation Therapy for Carcinoma of the Nasopharynx
Status: Enrolling
Updated: 2/9/2017
University of Florida Proton Therapy Institute
mi
from
Jacksonville, FL
Click here to add this to my saved trials
Preoperative Proton Radiotherapy for Retroperitoneal Sarcoma
A Pilot Study Investigating Preoperative Proton Radiotherapy for Retroperitoneal Sarcoma
Status: Enrolling
Updated:  2/9/2017
University of Florida Proton Therapy Institute
mi
from
Jacksonville, FL
Preoperative Proton Radiotherapy for Retroperitoneal Sarcoma
A Pilot Study Investigating Preoperative Proton Radiotherapy for Retroperitoneal Sarcoma
Status: Enrolling
Updated: 2/9/2017
University of Florida Proton Therapy Institute
mi
from
Jacksonville, FL
Click here to add this to my saved trials
Implementation of a Rapid Recovery Program in Gynecologic Oncology Surgery: A Pilot Study
Implementation of a Rapid Recovery Program in Gynecologic Oncology Surgery: A Pilot Study
Status: Enrolling
Updated:  2/9/2017
Masonic Cancer Center at University of Minnesota
mi
from
Minneapolis, MN
Implementation of a Rapid Recovery Program in Gynecologic Oncology Surgery: A Pilot Study
Implementation of a Rapid Recovery Program in Gynecologic Oncology Surgery: A Pilot Study
Status: Enrolling
Updated: 2/9/2017
Masonic Cancer Center at University of Minnesota
mi
from
Minneapolis, MN
Click here to add this to my saved trials
Stereotactic Body Radiation Therapy in Treating Patients With Metastatic Kidney Cancer Undergoing Surgery
Immunologic Impact of Stereotactic Body Radiation Therapy (SBRT) in Renal Cell Carcinoma
Status: Enrolling
Updated:  2/9/2017
Roswell Park Cancer Institute
mi
from
Buffalo, NY
Stereotactic Body Radiation Therapy in Treating Patients With Metastatic Kidney Cancer Undergoing Surgery
Immunologic Impact of Stereotactic Body Radiation Therapy (SBRT) in Renal Cell Carcinoma
Status: Enrolling
Updated: 2/9/2017
Roswell Park Cancer Institute
mi
from
Buffalo, NY
Click here to add this to my saved trials
A Phase I/II Study of BEZ235 in Patients With Advanced Solid Malignancies Enriched by Patients With Advanced Breast Cancer
A Phase I/II, Multi-center, Open-label Study of BEZ235, Administered Orally on a Continuous Daily Dosing Schedule in Adult Patients With Advanced Solid Malignancies Including Patients With Advanced Breast Cancer
Status: Enrolling
Updated:  2/13/2017
University of California at Los Angeles JonssonComprehensiveCancerCtr
mi
from
Los Angeles, CA
A Phase I/II Study of BEZ235 in Patients With Advanced Solid Malignancies Enriched by Patients With Advanced Breast Cancer
A Phase I/II, Multi-center, Open-label Study of BEZ235, Administered Orally on a Continuous Daily Dosing Schedule in Adult Patients With Advanced Solid Malignancies Including Patients With Advanced Breast Cancer
Status: Enrolling
Updated: 2/13/2017
University of California at Los Angeles JonssonComprehensiveCancerCtr
mi
from
Los Angeles, CA
Click here to add this to my saved trials
A Phase I/II Study of BEZ235 in Patients With Advanced Solid Malignancies Enriched by Patients With Advanced Breast Cancer
A Phase I/II, Multi-center, Open-label Study of BEZ235, Administered Orally on a Continuous Daily Dosing Schedule in Adult Patients With Advanced Solid Malignancies Including Patients With Advanced Breast Cancer
Status: Enrolling
Updated:  2/13/2017
Yale University School of Medicine YaleCancerCtr-ClinTrialsOffice
mi
from
New Haven, CT
A Phase I/II Study of BEZ235 in Patients With Advanced Solid Malignancies Enriched by Patients With Advanced Breast Cancer
A Phase I/II, Multi-center, Open-label Study of BEZ235, Administered Orally on a Continuous Daily Dosing Schedule in Adult Patients With Advanced Solid Malignancies Including Patients With Advanced Breast Cancer
Status: Enrolling
Updated: 2/13/2017
Yale University School of Medicine YaleCancerCtr-ClinTrialsOffice
mi
from
New Haven, CT
Click here to add this to my saved trials
A Phase I/II Study of BEZ235 in Patients With Advanced Solid Malignancies Enriched by Patients With Advanced Breast Cancer
A Phase I/II, Multi-center, Open-label Study of BEZ235, Administered Orally on a Continuous Daily Dosing Schedule in Adult Patients With Advanced Solid Malignancies Including Patients With Advanced Breast Cancer
Status: Enrolling
Updated:  2/13/2017
Dana Farber Cancer Institute Clinical Trials ProjectManager
mi
from
Boston, MA
A Phase I/II Study of BEZ235 in Patients With Advanced Solid Malignancies Enriched by Patients With Advanced Breast Cancer
A Phase I/II, Multi-center, Open-label Study of BEZ235, Administered Orally on a Continuous Daily Dosing Schedule in Adult Patients With Advanced Solid Malignancies Including Patients With Advanced Breast Cancer
Status: Enrolling
Updated: 2/13/2017
Dana Farber Cancer Institute Clinical Trials ProjectManager
mi
from
Boston, MA
Click here to add this to my saved trials
A Phase I/II Study of BEZ235 in Patients With Advanced Solid Malignancies Enriched by Patients With Advanced Breast Cancer
A Phase I/II, Multi-center, Open-label Study of BEZ235, Administered Orally on a Continuous Daily Dosing Schedule in Adult Patients With Advanced Solid Malignancies Including Patients With Advanced Breast Cancer
Status: Enrolling
Updated:  2/13/2017
Nevada Cancer Institute NVCC - Huntsman
mi
from
Las Vegas, NV
A Phase I/II Study of BEZ235 in Patients With Advanced Solid Malignancies Enriched by Patients With Advanced Breast Cancer
A Phase I/II, Multi-center, Open-label Study of BEZ235, Administered Orally on a Continuous Daily Dosing Schedule in Adult Patients With Advanced Solid Malignancies Including Patients With Advanced Breast Cancer
Status: Enrolling
Updated: 2/13/2017
Nevada Cancer Institute NVCC - Huntsman
mi
from
Las Vegas, NV
Click here to add this to my saved trials
A Phase I/II Study of BEZ235 in Patients With Advanced Solid Malignancies Enriched by Patients With Advanced Breast Cancer
A Phase I/II, Multi-center, Open-label Study of BEZ235, Administered Orally on a Continuous Daily Dosing Schedule in Adult Patients With Advanced Solid Malignancies Including Patients With Advanced Breast Cancer
Status: Enrolling
Updated:  2/13/2017
Cancer Centers of the Carolinas CCC Faris
mi
from
Greenville, SC
A Phase I/II Study of BEZ235 in Patients With Advanced Solid Malignancies Enriched by Patients With Advanced Breast Cancer
A Phase I/II, Multi-center, Open-label Study of BEZ235, Administered Orally on a Continuous Daily Dosing Schedule in Adult Patients With Advanced Solid Malignancies Including Patients With Advanced Breast Cancer
Status: Enrolling
Updated: 2/13/2017
Cancer Centers of the Carolinas CCC Faris
mi
from
Greenville, SC
Click here to add this to my saved trials
A Phase I/II Study of BEZ235 in Patients With Advanced Solid Malignancies Enriched by Patients With Advanced Breast Cancer
A Phase I/II, Multi-center, Open-label Study of BEZ235, Administered Orally on a Continuous Daily Dosing Schedule in Adult Patients With Advanced Solid Malignancies Including Patients With Advanced Breast Cancer
Status: Enrolling
Updated:  2/13/2017
Sarah Cannon Research Institute Dept.ofSarahCannonCancerCtr(2)
mi
from
Nashville, TN
A Phase I/II Study of BEZ235 in Patients With Advanced Solid Malignancies Enriched by Patients With Advanced Breast Cancer
A Phase I/II, Multi-center, Open-label Study of BEZ235, Administered Orally on a Continuous Daily Dosing Schedule in Adult Patients With Advanced Solid Malignancies Including Patients With Advanced Breast Cancer
Status: Enrolling
Updated: 2/13/2017
Sarah Cannon Research Institute Dept.ofSarahCannonCancerCtr(2)
mi
from
Nashville, TN
Click here to add this to my saved trials
A Phase I/II Study of BEZ235 in Patients With Advanced Solid Malignancies Enriched by Patients With Advanced Breast Cancer
A Phase I/II, Multi-center, Open-label Study of BEZ235, Administered Orally on a Continuous Daily Dosing Schedule in Adult Patients With Advanced Solid Malignancies Including Patients With Advanced Breast Cancer
Status: Enrolling
Updated:  2/13/2017
Baylor Health Care System/Sammons Cancer Center Baylor- Sammons
mi
from
Dallas, TX
A Phase I/II Study of BEZ235 in Patients With Advanced Solid Malignancies Enriched by Patients With Advanced Breast Cancer
A Phase I/II, Multi-center, Open-label Study of BEZ235, Administered Orally on a Continuous Daily Dosing Schedule in Adult Patients With Advanced Solid Malignancies Including Patients With Advanced Breast Cancer
Status: Enrolling
Updated: 2/13/2017
Baylor Health Care System/Sammons Cancer Center Baylor- Sammons
mi
from
Dallas, TX
Click here to add this to my saved trials
A Phase I/II Study of BEZ235 in Patients With Advanced Solid Malignancies Enriched by Patients With Advanced Breast Cancer
A Phase I/II, Multi-center, Open-label Study of BEZ235, Administered Orally on a Continuous Daily Dosing Schedule in Adult Patients With Advanced Solid Malignancies Including Patients With Advanced Breast Cancer
Status: Enrolling
Updated:  2/13/2017
University of Texas/MD Anderson Cancer Center Thoractic Head/Neck Med.Onc(2)
mi
from
Houston, TX
A Phase I/II Study of BEZ235 in Patients With Advanced Solid Malignancies Enriched by Patients With Advanced Breast Cancer
A Phase I/II, Multi-center, Open-label Study of BEZ235, Administered Orally on a Continuous Daily Dosing Schedule in Adult Patients With Advanced Solid Malignancies Including Patients With Advanced Breast Cancer
Status: Enrolling
Updated: 2/13/2017
University of Texas/MD Anderson Cancer Center Thoractic Head/Neck Med.Onc(2)
mi
from
Houston, TX
Click here to add this to my saved trials
A Phase I/II Study of BEZ235 in Patients With Advanced Solid Malignancies Enriched by Patients With Advanced Breast Cancer
A Phase I/II, Multi-center, Open-label Study of BEZ235, Administered Orally on a Continuous Daily Dosing Schedule in Adult Patients With Advanced Solid Malignancies Including Patients With Advanced Breast Cancer
Status: Enrolling
Updated:  2/13/2017
Tyler Cancer Center TCC
mi
from
Tyler, TX
A Phase I/II Study of BEZ235 in Patients With Advanced Solid Malignancies Enriched by Patients With Advanced Breast Cancer
A Phase I/II, Multi-center, Open-label Study of BEZ235, Administered Orally on a Continuous Daily Dosing Schedule in Adult Patients With Advanced Solid Malignancies Including Patients With Advanced Breast Cancer
Status: Enrolling
Updated: 2/13/2017
Tyler Cancer Center TCC
mi
from
Tyler, TX
Click here to add this to my saved trials
A Phase I/II Study of BEZ235 in Patients With Advanced Solid Malignancies Enriched by Patients With Advanced Breast Cancer
A Phase I/II, Multi-center, Open-label Study of BEZ235, Administered Orally on a Continuous Daily Dosing Schedule in Adult Patients With Advanced Solid Malignancies Including Patients With Advanced Breast Cancer
Status: Enrolling
Updated:  2/13/2017
Novartis Investigative Site
mi
from
Essen,
A Phase I/II Study of BEZ235 in Patients With Advanced Solid Malignancies Enriched by Patients With Advanced Breast Cancer
A Phase I/II, Multi-center, Open-label Study of BEZ235, Administered Orally on a Continuous Daily Dosing Schedule in Adult Patients With Advanced Solid Malignancies Including Patients With Advanced Breast Cancer
Status: Enrolling
Updated: 2/13/2017
Novartis Investigative Site
mi
from
Essen,
Click here to add this to my saved trials
Sunitinib and Irradiated Donor Lymphocytes in Treating Patients With Metastatic Kidney Cancer
Phase II Study of Sunitinib Plus Extended Courses of Irradiated Allogeneic Lymphocytes for Patients With Renal Cell Carcinoma (SPECIAL Trial)
Status: Enrolling
Updated:  2/13/2017
Rutgers Cancer Institute of New Jersey
mi
from
New Brunswick, NJ
Sunitinib and Irradiated Donor Lymphocytes in Treating Patients With Metastatic Kidney Cancer
Phase II Study of Sunitinib Plus Extended Courses of Irradiated Allogeneic Lymphocytes for Patients With Renal Cell Carcinoma (SPECIAL Trial)
Status: Enrolling
Updated: 2/13/2017
Rutgers Cancer Institute of New Jersey
mi
from
New Brunswick, NJ
Click here to add this to my saved trials
Phase I Study of CS-7017 and Bexarotene
A Phase I Study of a Combination of the Proteosome Proliferator-Activated Receptor Gamma Agonist, CS-7017 and the Retinoid X Receptor Agonist, Bexarotene
Status: Enrolling
Updated:  2/13/2017
Georgetown Lombardi Comprehensive Cancer Center
mi
from
Washington,
Phase I Study of CS-7017 and Bexarotene
A Phase I Study of a Combination of the Proteosome Proliferator-Activated Receptor Gamma Agonist, CS-7017 and the Retinoid X Receptor Agonist, Bexarotene
Status: Enrolling
Updated: 2/13/2017
Georgetown Lombardi Comprehensive Cancer Center
mi
from
Washington,
Click here to add this to my saved trials
Study of Gemcitabine and Abraxane for Pancreas Cancer
A Phase II Study of Gemcitabine and Nanoparticle-Bound Paclitaxel as Second Line Therapy in Patients With Metastatic Pancreatic Cancer
Status: Enrolling
Updated:  2/13/2017
Georgetown Lombardi Comprehensive Cancer Center
mi
from
Washington,
Study of Gemcitabine and Abraxane for Pancreas Cancer
A Phase II Study of Gemcitabine and Nanoparticle-Bound Paclitaxel as Second Line Therapy in Patients With Metastatic Pancreatic Cancer
Status: Enrolling
Updated: 2/13/2017
Georgetown Lombardi Comprehensive Cancer Center
mi
from
Washington,
Click here to add this to my saved trials
Comparison Between the 19 and 22 Gauge Needles for Core Tissue Procurement During EUS-guided Procedures
Comparison Between the 19 and 22 Gauge Needles for Core Tissue Procurement During EUS-guided Procedures
Status: Enrolling
Updated:  2/13/2017
Florida Hospital
mi
from
Orlando, FL
Comparison Between the 19 and 22 Gauge Needles for Core Tissue Procurement During EUS-guided Procedures
Comparison Between the 19 and 22 Gauge Needles for Core Tissue Procurement During EUS-guided Procedures
Status: Enrolling
Updated: 2/13/2017
Florida Hospital
mi
from
Orlando, FL
Click here to add this to my saved trials
A Study of Ad-RTS-hIL-12 With Veledimex in Subjects With Breast Cancer
A Single-arm, Open-label Study of Ad-RTS-hIL-12 + Veledimex Following First-, Second-, or Third-Line Standard Treatment in Subjects With Locally Advanced or Metastatic Breast Cancer
Status: Enrolling
Updated:  2/13/2017
Memorial Sloan Kettering Cancer Center
mi
from
New York, NY
A Study of Ad-RTS-hIL-12 With Veledimex in Subjects With Breast Cancer
A Single-arm, Open-label Study of Ad-RTS-hIL-12 + Veledimex Following First-, Second-, or Third-Line Standard Treatment in Subjects With Locally Advanced or Metastatic Breast Cancer
Status: Enrolling
Updated: 2/13/2017
Memorial Sloan Kettering Cancer Center
mi
from
New York, NY
Click here to add this to my saved trials
Comparison of Colon Adenoma Detection Rate Using Two Distal Colonoscope Attachments
Comparison of Colon Adenoma Detection Rate Using Two Distal Colonoscope Attachments
Status: Enrolling
Updated:  2/13/2017
University of California-Davis
mi
from
Sacramento, CA
Comparison of Colon Adenoma Detection Rate Using Two Distal Colonoscope Attachments
Comparison of Colon Adenoma Detection Rate Using Two Distal Colonoscope Attachments
Status: Enrolling
Updated: 2/13/2017
University of California-Davis
mi
from
Sacramento, CA
Click here to add this to my saved trials
Protocol for Postmenopausal Women at Increased Risk of Developing Breast Cancer
Correlation of SNP Patterns With Fine Needle Aspiration Cytomorphology in High Risk Postmenopausal Women
Status: Enrolling
Updated:  2/13/2017
University of Kansas Medical Center
mi
from
Kansas City, KA
Protocol for Postmenopausal Women at Increased Risk of Developing Breast Cancer
Correlation of SNP Patterns With Fine Needle Aspiration Cytomorphology in High Risk Postmenopausal Women
Status: Enrolling
Updated: 2/13/2017
University of Kansas Medical Center
mi
from
Kansas City, KA
Click here to add this to my saved trials
Relationship Between Endoscopic Ultrasound Staging and Degree of Stricture in Esophageal Cancer
Relationship Between Endoscopic Ultrasound Staging and Degree of Stricture in Esophageal Cancer
Status: Enrolling
Updated:  2/13/2017
Florida Hospital Center for Interventional Endoscopy
mi
from
Orlando, FL
Relationship Between Endoscopic Ultrasound Staging and Degree of Stricture in Esophageal Cancer
Relationship Between Endoscopic Ultrasound Staging and Degree of Stricture in Esophageal Cancer
Status: Enrolling
Updated: 2/13/2017
Florida Hospital Center for Interventional Endoscopy
mi
from
Orlando, FL
Click here to add this to my saved trials
Proton Therapy for Chordomas and/or Chondrosarcomas
A Clinical Outcomes Protocol of Proton Beam Radiation Therapy for Chordomas and/or Chondrosarcomas of the Base of Skull and/or Spine
Status: Enrolling
Updated:  2/14/2017
University of Florida Proton Therapy Institute
mi
from
Jacksonville, FL
Proton Therapy for Chordomas and/or Chondrosarcomas
A Clinical Outcomes Protocol of Proton Beam Radiation Therapy for Chordomas and/or Chondrosarcomas of the Base of Skull and/or Spine
Status: Enrolling
Updated: 2/14/2017
University of Florida Proton Therapy Institute
mi
from
Jacksonville, FL
Click here to add this to my saved trials
A Study of LY2875358 in Participants With Advanced Cancer
A Phase 1 Study of LY2875358 in Patients With Advanced Cancer
Status: Enrolling
Updated:  2/14/2017
The University of California, San Diego
mi
from
La Jolla, CA
A Study of LY2875358 in Participants With Advanced Cancer
A Phase 1 Study of LY2875358 in Patients With Advanced Cancer
Status: Enrolling
Updated: 2/14/2017
The University of California, San Diego
mi
from
La Jolla, CA
Click here to add this to my saved trials
A Study of LY2875358 in Participants With Advanced Cancer
A Phase 1 Study of LY2875358 in Patients With Advanced Cancer
Status: Enrolling
Updated:  2/14/2017
Cedars-Sinai Medical Center
mi
from
Los Angeles, CA
A Study of LY2875358 in Participants With Advanced Cancer
A Phase 1 Study of LY2875358 in Patients With Advanced Cancer
Status: Enrolling
Updated: 2/14/2017
Cedars-Sinai Medical Center
mi
from
Los Angeles, CA
Click here to add this to my saved trials
A Study of LY2875358 in Participants With Advanced Cancer
A Phase 1 Study of LY2875358 in Patients With Advanced Cancer
Status: Enrolling
Updated:  2/14/2017
Ucla
mi
from
Santa Monica, CA
A Study of LY2875358 in Participants With Advanced Cancer
A Phase 1 Study of LY2875358 in Patients With Advanced Cancer
Status: Enrolling
Updated: 2/14/2017
Ucla
mi
from
Santa Monica, CA
Click here to add this to my saved trials
A Study of LY2875358 in Participants With Advanced Cancer
A Phase 1 Study of LY2875358 in Patients With Advanced Cancer
Status: Enrolling
Updated:  2/14/2017
Massachusetts General Hospital
mi
from
Boston, MA
A Study of LY2875358 in Participants With Advanced Cancer
A Phase 1 Study of LY2875358 in Patients With Advanced Cancer
Status: Enrolling
Updated: 2/14/2017
Massachusetts General Hospital
mi
from
Boston, MA
Click here to add this to my saved trials
A Study of LY2875358 in Participants With Advanced Cancer
A Phase 1 Study of LY2875358 in Patients With Advanced Cancer
Status: Enrolling
Updated:  2/14/2017
University of Michigan
mi
from
Ann Arbor, MI
A Study of LY2875358 in Participants With Advanced Cancer
A Phase 1 Study of LY2875358 in Patients With Advanced Cancer
Status: Enrolling
Updated: 2/14/2017
University of Michigan
mi
from
Ann Arbor, MI
Click here to add this to my saved trials
A Study of LY2875358 in Participants With Advanced Cancer
A Phase 1 Study of LY2875358 in Patients With Advanced Cancer
Status: Enrolling
Updated:  2/14/2017
Thomas Jefferson University
mi
from
Philadelphia, PA
A Study of LY2875358 in Participants With Advanced Cancer
A Phase 1 Study of LY2875358 in Patients With Advanced Cancer
Status: Enrolling
Updated: 2/14/2017
Thomas Jefferson University
mi
from
Philadelphia, PA
Click here to add this to my saved trials
A Study of LY2875358 in Participants With Advanced Cancer
A Phase 1 Study of LY2875358 in Patients With Advanced Cancer
Status: Enrolling
Updated:  2/14/2017
University of California at San Francisco
mi
from
San Francisco, CA
A Study of LY2875358 in Participants With Advanced Cancer
A Phase 1 Study of LY2875358 in Patients With Advanced Cancer
Status: Enrolling
Updated: 2/14/2017
University of California at San Francisco
mi
from
San Francisco, CA
Click here to add this to my saved trials
A Study of LY2875358 in Participants With Advanced Cancer
A Phase 1 Study of LY2875358 in Patients With Advanced Cancer
Status: Enrolling
Updated:  2/14/2017
Mayo Clinic, Jacksonville
mi
from
Jacksonville, FL
A Study of LY2875358 in Participants With Advanced Cancer
A Phase 1 Study of LY2875358 in Patients With Advanced Cancer
Status: Enrolling
Updated: 2/14/2017
Mayo Clinic, Jacksonville
mi
from
Jacksonville, FL
Click here to add this to my saved trials
A Study of LY2875358 in Participants With Advanced Cancer
A Phase 1 Study of LY2875358 in Patients With Advanced Cancer
Status: Enrolling
Updated:  2/14/2017
Emory University
mi
from
Atlanta, GA
A Study of LY2875358 in Participants With Advanced Cancer
A Phase 1 Study of LY2875358 in Patients With Advanced Cancer
Status: Enrolling
Updated: 2/14/2017
Emory University
mi
from
Atlanta, GA
Click here to add this to my saved trials
A Study of LY2875358 in Participants With Advanced Cancer
A Phase 1 Study of LY2875358 in Patients With Advanced Cancer
Status: Enrolling
Updated:  2/14/2017
The Mayo Clinic
mi
from
Rochester, MN
A Study of LY2875358 in Participants With Advanced Cancer
A Phase 1 Study of LY2875358 in Patients With Advanced Cancer
Status: Enrolling
Updated: 2/14/2017
The Mayo Clinic
mi
from
Rochester, MN
Click here to add this to my saved trials
Safety and Efficacy of Radiation/Cetuximab Plus EGFR Antisense DNA for Head and Neck Squamous Cell Carcinoma
Safety and Efficacy Evaluation of Radiation and Cetuximab Plus Intratumoral EGFR Antisense DNA Patients With Locally Advanced Head and Neck Squamous Cell Carcinoma
Status: Enrolling
Updated:  2/14/2017
Hillman Cancer Center
mi
from
Pittsburgh, PA
Safety and Efficacy of Radiation/Cetuximab Plus EGFR Antisense DNA for Head and Neck Squamous Cell Carcinoma
Safety and Efficacy Evaluation of Radiation and Cetuximab Plus Intratumoral EGFR Antisense DNA Patients With Locally Advanced Head and Neck Squamous Cell Carcinoma
Status: Enrolling
Updated: 2/14/2017
Hillman Cancer Center
mi
from
Pittsburgh, PA
Click here to add this to my saved trials
Hydroxychloroquine, Capecitabine, Oxaliplatin, and Bevacizumab in Treating Patients With Metastatic Colorectal Cancer
Autophagy and Anti-Angiogenesis in Metastatic Colorectal Carcinoma: A Phase II Trial of Hydroxychloroquine to Augment Effectiveness of XELOX-Bevacizumab. A Study of the Cancer Institute of New Jersey Oncology Group (CINJOG)
Status: Enrolling
Updated:  2/14/2017
Cancer Institute of New Jersey at Hamilton
mi
from
Hamilton, NJ
Hydroxychloroquine, Capecitabine, Oxaliplatin, and Bevacizumab in Treating Patients With Metastatic Colorectal Cancer
Autophagy and Anti-Angiogenesis in Metastatic Colorectal Carcinoma: A Phase II Trial of Hydroxychloroquine to Augment Effectiveness of XELOX-Bevacizumab. A Study of the Cancer Institute of New Jersey Oncology Group (CINJOG)
Status: Enrolling
Updated: 2/14/2017
Cancer Institute of New Jersey at Hamilton
mi
from
Hamilton, NJ
Click here to add this to my saved trials
Hydroxychloroquine, Capecitabine, Oxaliplatin, and Bevacizumab in Treating Patients With Metastatic Colorectal Cancer
Autophagy and Anti-Angiogenesis in Metastatic Colorectal Carcinoma: A Phase II Trial of Hydroxychloroquine to Augment Effectiveness of XELOX-Bevacizumab. A Study of the Cancer Institute of New Jersey Oncology Group (CINJOG)
Status: Enrolling
Updated:  2/14/2017
New Jersey Medical School-University Hospital Cancer Center
mi
from
Newark, NJ
Hydroxychloroquine, Capecitabine, Oxaliplatin, and Bevacizumab in Treating Patients With Metastatic Colorectal Cancer
Autophagy and Anti-Angiogenesis in Metastatic Colorectal Carcinoma: A Phase II Trial of Hydroxychloroquine to Augment Effectiveness of XELOX-Bevacizumab. A Study of the Cancer Institute of New Jersey Oncology Group (CINJOG)
Status: Enrolling
Updated: 2/14/2017
New Jersey Medical School-University Hospital Cancer Center
mi
from
Newark, NJ
Click here to add this to my saved trials
Hydroxychloroquine, Capecitabine, Oxaliplatin, and Bevacizumab in Treating Patients With Metastatic Colorectal Cancer
Autophagy and Anti-Angiogenesis in Metastatic Colorectal Carcinoma: A Phase II Trial of Hydroxychloroquine to Augment Effectiveness of XELOX-Bevacizumab. A Study of the Cancer Institute of New Jersey Oncology Group (CINJOG)
Status: Enrolling
Updated:  2/14/2017
Rutgers Cancer Institute of New Jersey
mi
from
New Brunswick, NJ
Hydroxychloroquine, Capecitabine, Oxaliplatin, and Bevacizumab in Treating Patients With Metastatic Colorectal Cancer
Autophagy and Anti-Angiogenesis in Metastatic Colorectal Carcinoma: A Phase II Trial of Hydroxychloroquine to Augment Effectiveness of XELOX-Bevacizumab. A Study of the Cancer Institute of New Jersey Oncology Group (CINJOG)
Status: Enrolling
Updated: 2/14/2017
Rutgers Cancer Institute of New Jersey
mi
from
New Brunswick, NJ
Click here to add this to my saved trials
Hydroxychloroquine, Capecitabine, Oxaliplatin, and Bevacizumab in Treating Patients With Metastatic Colorectal Cancer
Autophagy and Anti-Angiogenesis in Metastatic Colorectal Carcinoma: A Phase II Trial of Hydroxychloroquine to Augment Effectiveness of XELOX-Bevacizumab. A Study of the Cancer Institute of New Jersey Oncology Group (CINJOG)
Status: Enrolling
Updated:  2/14/2017
Cooper Hospital University Medical Center
mi
from
Camden, NJ
Hydroxychloroquine, Capecitabine, Oxaliplatin, and Bevacizumab in Treating Patients With Metastatic Colorectal Cancer
Autophagy and Anti-Angiogenesis in Metastatic Colorectal Carcinoma: A Phase II Trial of Hydroxychloroquine to Augment Effectiveness of XELOX-Bevacizumab. A Study of the Cancer Institute of New Jersey Oncology Group (CINJOG)
Status: Enrolling
Updated: 2/14/2017
Cooper Hospital University Medical Center
mi
from
Camden, NJ
Click here to add this to my saved trials
Dovitinib Lactate, Gemcitabine Hydrochloride, and Capecitabine in Treating Patients With Advanced or Metastatic Solid Tumors, Pancreatic Cancer and Biliary Cancers
Phase I Study of Dovitinib (TKI258) in Combination With Gemcitabine and Capecitabine in Advanced Solid Tumors, Pancreatic Cancer and Biliary Cancers
Status: Enrolling
Updated:  2/14/2017
Roswell Park Cancer Institute
mi
from
Buffalo, NY
Dovitinib Lactate, Gemcitabine Hydrochloride, and Capecitabine in Treating Patients With Advanced or Metastatic Solid Tumors, Pancreatic Cancer and Biliary Cancers
Phase I Study of Dovitinib (TKI258) in Combination With Gemcitabine and Capecitabine in Advanced Solid Tumors, Pancreatic Cancer and Biliary Cancers
Status: Enrolling
Updated: 2/14/2017
Roswell Park Cancer Institute
mi
from
Buffalo, NY
Click here to add this to my saved trials
A Study of MEK162 and AMG 479 in Patients With Selected Solid Tumors
A Phase Ib/II Open-label, Multi-center Study of the Combination of MEK162 Plus AMG 479 (Ganitumab) in Adult Patients With Selected Advanced Solid Tumors
Status: Enrolling
Updated:  2/14/2017
Massachusetts General Hospital Mass General 2
mi
from
Boston, MA
A Study of MEK162 and AMG 479 in Patients With Selected Solid Tumors
A Phase Ib/II Open-label, Multi-center Study of the Combination of MEK162 Plus AMG 479 (Ganitumab) in Adult Patients With Selected Advanced Solid Tumors
Status: Enrolling
Updated: 2/14/2017
Massachusetts General Hospital Mass General 2
mi
from
Boston, MA
Click here to add this to my saved trials
A Study of MEK162 and AMG 479 in Patients With Selected Solid Tumors
A Phase Ib/II Open-label, Multi-center Study of the Combination of MEK162 Plus AMG 479 (Ganitumab) in Adult Patients With Selected Advanced Solid Tumors
Status: Enrolling
Updated:  2/14/2017
University of Utah / Huntsman Cancer Institute Huntsman
mi
from
Salt Lake City, UT
A Study of MEK162 and AMG 479 in Patients With Selected Solid Tumors
A Phase Ib/II Open-label, Multi-center Study of the Combination of MEK162 Plus AMG 479 (Ganitumab) in Adult Patients With Selected Advanced Solid Tumors
Status: Enrolling
Updated: 2/14/2017
University of Utah / Huntsman Cancer Institute Huntsman
mi
from
Salt Lake City, UT
Click here to add this to my saved trials
A Study of MEK162 and AMG 479 in Patients With Selected Solid Tumors
A Phase Ib/II Open-label, Multi-center Study of the Combination of MEK162 Plus AMG 479 (Ganitumab) in Adult Patients With Selected Advanced Solid Tumors
Status: Enrolling
Updated:  2/14/2017
Novartis Investigative Site
mi
from
Parkville,
A Study of MEK162 and AMG 479 in Patients With Selected Solid Tumors
A Phase Ib/II Open-label, Multi-center Study of the Combination of MEK162 Plus AMG 479 (Ganitumab) in Adult Patients With Selected Advanced Solid Tumors
Status: Enrolling
Updated: 2/14/2017
Novartis Investigative Site
mi
from
Parkville,
Click here to add this to my saved trials
Detection of Advanced Colorectal Neoplasia by Stool DNA in Inflammatory Bowel Disease
Detection of Advanced Colorectal Neoplasia by Stool DNA in Inflammatory Bowel Disease: OCEANIA Study
Status: Enrolling
Updated:  2/16/2017
Mayo Clinic
mi
from
Phoenix, AZ
Detection of Advanced Colorectal Neoplasia by Stool DNA in Inflammatory Bowel Disease
Detection of Advanced Colorectal Neoplasia by Stool DNA in Inflammatory Bowel Disease: OCEANIA Study
Status: Enrolling
Updated: 2/16/2017
Mayo Clinic
mi
from
Phoenix, AZ
Click here to add this to my saved trials
Detection of Advanced Colorectal Neoplasia by Stool DNA in Inflammatory Bowel Disease
Detection of Advanced Colorectal Neoplasia by Stool DNA in Inflammatory Bowel Disease: OCEANIA Study
Status: Enrolling
Updated:  2/16/2017
UC San Diego Medical Center
mi
from
La Jolla, CA
Detection of Advanced Colorectal Neoplasia by Stool DNA in Inflammatory Bowel Disease
Detection of Advanced Colorectal Neoplasia by Stool DNA in Inflammatory Bowel Disease: OCEANIA Study
Status: Enrolling
Updated: 2/16/2017
UC San Diego Medical Center
mi
from
La Jolla, CA
Click here to add this to my saved trials